z-logo
open-access-imgOpen Access
Functional characterization of a novel CSF1R mutation causing hereditary diffuse leukoencephalopathy with spheroids
Author(s) -
Kraya Torsten,
Quandt Dagmar,
Pfirrmann Thorsten,
Kindermann Andrea,
Lampe Leonie,
Schroeter Matthias L.,
Kohlhase Jürgen,
Stoevesandt Dietrich,
Hoffmann Katrin,
VillavicencioLorini Pablo
Publication year - 2019
Publication title -
molecular genetics and genomic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.765
H-Index - 29
ISSN - 2324-9269
DOI - 10.1002/mgg3.595
Subject(s) - mertk , autophosphorylation , mutation , microglia , leukoencephalopathy , cancer research , biology , tyrosine kinase , receptor tyrosine kinase , receptor , medicine , microbiology and biotechnology , immunology , kinase , gene , genetics , inflammation , pathology , disease , protein kinase a
Background Colony‐stimulating factor 1 receptor is a tyrosine kinase transmembrane protein that mediates proliferation, differentiation, and survival of monocytes/macrophages and microglia. CSF1R gene mutations cause hereditary diffuse leukoencephalopathy with spheroids (HDLS), an autosomal‐dominantly inherited microgliopathy, leading to early onset dementia with high lethality. Methods By interdisciplinary assessment of a complex neuropsychiatric condition in a 44‐year old female patient, we narrowed down the genetic diagnostic to CSF1R gene sequencing. Flow cytometric analyses of uncultivated peripheral blood monocytes were conducted sequentially to measure the cell surface CSF1 receptor and autophosphorylation levels. Monocyte subpopulations were monitored during disease progression. Results We identified a novel heterozygous deletion–insertion mutation c.2527_2530delinsGGCA, p.(Ile843_Leu844delinsGlyIle) in our patient with initial signs of HDLS. Marginally elevated cell surface CSF1 receptor levels with increased Tyr723 autophosphorylation suggest an enhanced receptor activity. Furthermore, we observed a shift in monocyte subpopulations during disease course. Conclusion Our data indicate a mutation‐related CSF1R gain‐of‐function, accompanied by an altered composition of the peripheral innate immune cells in our patient with HDLS. Since pharmacological targeting of CSF1R with tyrosine kinase inhibitors prevents disease progression in mouse models of neurodegenerative disorders, a potential pharmacological benefit of CSF1R inhibition remains to be elucidated for patients with HDLS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here